Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLAF: FOLFIRI + Aflibercept in Oxaliplatin-pretreated mCRC
NCT02970916Phase 2Completed
- Sponsor
- Spanish Cooperative Group for Digestive Tumour Therapy
- Start
- Nov 2016
- Primary completion
- May 2018
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aflibercept in colorectal cancer (metastatic) (mCRC), sponsored by Spanish Cooperative Group for Digestive Tumour Therapy. Primary endpoint: Progression-Free Survival at 30 months. Started Nov 2016; status: completed.
02
Drugs
aflibercept
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT02970916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02970916.